UNASSIGNED: In this study, 275 @entity1 in use of @entity15833 were retrospectively followed-up for three years to evaluate risk factors involved in @entity8 . Analysis of variance (ANOVA) and Tukey's test were used to verify any differences in @entity1011 levels and estimated clearance (CKD-EPI equation) at 0, 6, 12, 24 and 36 months, adjusting for the co-variables sex, skin color, age >50 years, arterial @entity101 , @entity6 and the use of the @entity486 -boosted protease inhibitors (PI/r) @entity5195 /r or @entity5194 /r. The software package STATISTICA 10(  ) was used for statistical analysis. The @entity1 ' mean age was 43.2  10.7 years. @entity101 ( @entity101 ) and @entity6 were found in 20.4% and 8.7% of the @entity1 , respectively. Overall, 96.7% were on @entity15833 associated with @entity16332 (TDF+ @entity16332 ), 39.3% on @entity5195 /r, 29.8% on efavirenz, and 17.6% on @entity5194 /r. At 24 months, there was a statistically significant difference in estimated @entity1011 clearance (CKD-EPI) when the co-variables male (F=3.95; p=0.048), @entity101 (F=6.964; p=0.009), and age over 50 years (F=45.81; p<0.001) were taken into consideration. Analysis of the co-variable use of @entity5194 /r showed a tendency toward an increased risk over time (F=2.437; p=0.063); however, no significant time interaction was seen. At 36-month, a statistically significant difference was found for age over 50 years, (F=32.02; p<0.05) and there was a significant time-by-sex interaction (F=3.117; p=0.0149). TDF was discontinued in 12 @entity1 , one because of a @entity2249 (0.7%) and 11 due to nephrotoxicity (4%). Of these latter cases, 9/11 @entity1 were also using protease inhibitors. These data strongly alert that @entity15833 use should be individualized with careful attention to renal function especially in male @entity1 , over 50 years, with @entity101 , and probably those on @entity11254 /r.

Nephrotoxicity during XXXX treatment: a three-year follow-up study in a Brazilian reference clinic.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['impaired renal function'] @entity2249 :: ('MESH:D005265', 'Disease') :: ['femoral neck fracture'] @entity5194 :: ('MESH:C413408', 'Chemical') :: ['atazanavir'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'Systemic arterial hypertension', 'SAH'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity16332 :: ('MESH:D019259', 'Chemical') :: ['lamivudine', '3TC'] @entity11254 :: ('265294', 'Species') :: ['ATV'] @entity5195 :: ('MESH:D061466', 'Chemical') :: ['lopinavir'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity15833 :: ('MESH:C096918', 'Chemical') :: ['tenofovir'] @entity486 :: ('MESH:D019438', 'Chemical') :: ['ritonavir']
@entity15833 :: (MESH:C096918,Chemical) :: ['tenofovir']
